Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FDX104
- Development stage
- Phase 2
- Lead developer
- Vyne Therapeutics
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Topical
01
Overview
FDX104 is an investigational topical foam formulation containing 4% doxycycline hyclate, developed to prevent or reduce acneiform rash induced by epidermal growth factor receptor (EGFR)–targeted therapies and other targeted antibody treatments in cancer patients.[1][3][4][5][11] By delivering high local concentrations of the tetracycline-class antibiotic doxycycline directly to the skin while minimizing systemic exposure, FDX104 aims to leverage doxycycline’s anti-inflammatory and antimicrobial properties to mitigate EGFR inhibitor–associated rash, thereby improving quality of life and helping patients remain on optimal anticancer regimens.[3][4][6][8]
- Other names
- doxycycline hyclate foam 4%
02
Targets
Bacterial Ribosome
Beyond the preview
Go deeper on FDX104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FDX104.